Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma

Technology appraisal guidance
Reference number: TA1160
Published: 03 June 2026

NIHRIO BN: 33898-Durvalumab-FLOT-for-Gastro-Oesophageal-Junction-Cancer-V1.0-SEP2023-NON-CONF.pdf (nihr.ac.uk)

This page was last updated: 25 October 2023